Abstract
We have investigated the potential of 18FDG detection to locate identify? To locate an occult disease in cancer patients with an isolated elevation of a circulating tumour marker without any evidence of malignancies. Methods. – Six hundred ninety-nine patients, 31 to 78 years, previously treated for breast cancer ( n = 291), colorectal cancer ( n = 201), ovarian cancer ( n = 123) or an epidermoïd carcinoma (n = 84) were studied. 18FDG was performed with a dedicated PET camera associated to a CT. Results were correlated with other conventional imaging methods, pathology results or clinical evolution. Results. – 18FDG scans were positive for 647 patients. With an overall sensitivity of 96.7% and a positive predictive value of 94.1%, 18FDG has identified metastatic relapse with a lead time of 4–11 months in 87.1% of all patients. Conclusion. – These promising results should convince oncologists to design new prospective studies comparing the standard practice to early treatment based on blood tumour marker measurement and 18FDG assessment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
